Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BYFAVO vs A/T/S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.
A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Improvement of excessive daytime sleepiness in adult patients with obstructive sleep apnea (OSA) as an adjunct to upper airway stimulation therapy
Treatment of acne vulgaris (FDA-approved indication),Treatment of bacterial infections caused by susceptible organisms (off-label use for acne is the primary use)
For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.
Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.
Terminal elimination half-life is approximately 2-4 hours; clinical context: requires continuous infusion for sustained effect, as rapid clearance may lead to loss of efficacy.
Terminal elimination half-life: 1–2 hours (prolonged in hepatic impairment).
Primarily metabolized by CYP3A4 and CYP2D6, with minor contribution from CYP1A2.
Antithrombin is a glycoprotein; its metabolism involves cellular uptake and catabolism, but specific CYP450 enzymes are not involved. Degradation occurs via proteolysis and reticuloendothelial system clearance.
Renal excretion accounts for approximately 90% of the administered dose, with <5% as unchanged drug. Biliary/fecal elimination is minimal (<5%).
Renal: 10-20% (active drug and metabolites); Fecal: minimal; Biliary: not significant.
Approximately 70-80% bound to human serum albumin and alpha-1-acid glycoprotein.
70-90% bound to serum albumin.
Volume of distribution (Vd) is 0.3-0.5 L/kg; clinical meaning: indicates moderate distribution into tissues, not extensive peripheral sequestration.
0.5–0.8 L/kg (low Vd, minimal tissue penetration).
Bioavailability is not applicable for intravenous formulation; oral bioavailability is negligible due to extensive first-pass metabolism (<5% if administered orally).
Topical: 1–5% (minimal systemic absorption).
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), consider reduced infusion rate due to prolonged recovery times; specific dose not established.
No specific adjustment required; drug is not renally eliminated.
Child-Pugh A and B: No adjustment. Child-Pugh C: Reduce infusion rate by 50% and monitor for prolonged sedation; starting infusion at 0.75 mg/kg/hour is recommended.
No specific adjustment; antithrombin is produced in the liver, but exogenous replacement does not require dose adjustment in hepatic impairment.
Not approved for pediatric patients <18 years of age. Safety and efficacy not established.
Dosing based on weight and antithrombin levels; typical initial dose 30-50 IU/kg, followed by maintenance to achieve target levels. Clinical trial data limited in neonates.
For patients ≥65 years, consider lower initial infusion rate (1 mg/kg/hour) and reduce bolus doses; titrate carefully due to increased sensitivity and slower emergence from anesthesia.
No specific adjustment; use standard dosing with monitoring of antithrombin activity and bleeding risk.
Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).
None.
Risk of transient ischemic attacks and seizures; discontinue use if neurological symptoms occur.,May cause dose-related increases in blood pressure and heart rate; monitor cardiovascular status.,Not recommended in patients with unstable cardiovascular disease, recent myocardial infarction, or stroke.,Potential for drug interactions with strong CYP3A4 inhibitors or inducers.,May cause insomnia, anxiety, or restlessness.
Hypersensitivity reactions including anaphylaxis have occurred.,Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Use with caution in patients with hepatic impairment.,Potential for QT prolongation and ventricular arrhythmias, especially with intravenous administration or concomitant drugs that prolong QT interval.
Hypersensitivity to BYFAVO or any of its components,Severe hepatic impairment (Child-Pugh Class C)
Hypersensitivity to erythromycin or any macrolide antibiotic.,Use with caution in patients with pre-existing QT prolongation or electrolyte abnormalities (relative contraindication).
No specific food interactions are reported. However, because sedation may cause nausea, avoid heavy meals immediately before sedation. Grapefruit juice does not significantly interact with remimazolam.
No specific food interactions. Avoid excessive alcohol consumption as it may increase skin dryness.
BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Effective contraception required.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk to fetus is low across all trimesters.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). Topical use results in negligible systemic exposure; unlikely to cause adverse effects in nursing infants.
No pharmacokinetic data in pregnancy; standard dosing is not recommended as drug is contraindicated. If use is unavoidable, no specific dose adjustment guidelines exist; use with extreme caution and consider alternative therapy.
No dose adjustment required. Systemic absorption from topical application is minimal and not significantly altered by pregnancy-related pharmacokinetic changes.
BYFAVO (remimazolam) is an ultra-short-acting benzodiazepine for procedural sedation. Onset within 1-2 minutes, recovery typically within 10 minutes. Flumazenil is the reversal agent. Monitor for respiratory depression; have resuscitation equipment available. Avoid in severe hepatic impairment. Coadministration with opioids increases sedation depth; reduce doses accordingly.
A/T/S (erythromycin 2% topical solution) is indicated for acne vulgaris. Avoid contact with eyes, mouth, and mucous membranes. May cause skin dryness or irritation; use moisturizer. Effectiveness may decrease with prolonged use due to bacterial resistance. Not recommended for use with other topical erythromycin products or clindamycin to avoid antagonism.
You will be closely monitored during the procedure. Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,Inform your healthcare provider if you have a history of liver disease, glaucoma, or substance abuse.,Do not consume alcohol for at least 24 hours after sedation.,You may experience temporary memory loss or drowsiness; arrange for a responsible adult to accompany you home.,Report any unusual side effects such as prolonged drowsiness, difficulty breathing, or allergic reactions (rash, swelling) to your doctor immediately.
Apply a thin layer to affected areas twice daily after washing.,Avoid contact with eyes, lips, and mouth; if contact occurs, rinse thoroughly with water.,May cause stinging, burning, or peeling; if irritation persists, consult your doctor.,Use sunscreen daily as this medication may increase sensitivity to sunlight.,Do not use more than prescribed; overuse may increase side effects without improving results.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep away from open flames or heat sources; product is flammable.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BYFAVO vs A/T/S, answered by our medical review team.
BYFAVO is a Benzodiazepine that works by Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.. A/T/S is a Macrolide antibiotic that works by A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BYFAVO and A/T/S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BYFAVO is: For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.. The standard adult dose of A/T/S is: Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BYFAVO and A/T/S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BYFAVO is classified as Category C. BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. A/T/S is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.